logo
Plus   Neg
Share
Email

Amgen To Acquire 20.5% Stake In BeiGene For Approx. $2.7 Bln - Quick Facts

Amgen (AMGN) has entered into a strategic collaboration with BeiGene that will accelerate Amgen's plans to expand its oncology presence in China. BeiGene is a research-based, oncology-focused biotechnology company. Amgen will acquire a 20.5 percent stake in BeiGene for approximately $2.7 billion. This represents a purchase price of $174.85 per BeiGene American Depositary Share on NASDAQ.

Amgen and BeiGene will collaborate to advance 20 medicines from Amgen's oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion. Amgen will pay royalties to BeiGene on the sales of these products outside of China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020. Shares of Deutsche Lufthansa AG were losing around 3 percent in German trading after the airline reported Thursday a loss in its second quarter, compared to prior year's profit with sharply lower revenues with collapse in demand for air travel due to the Corona pandemic. Going ahead, the airline projects a clearly negative adjusted EBIT in the second half of 2020 and a further significant decline Former Google engineer Anthony Levandowski was sentenced by a U.S. judge to eighteen months in prison for stealing trade secrets from Google's self-driving car unit before he defected to Uber's rival unit. Levandowski admitted that from 2009 to 2016, he worked in Google's self-driving car program, known then as Project Chauffer.
Follow RTT